Amgen has agreed to acquire Dark Blue Therapeutics in a deal valued at up to $840 million, as the biopharmaceutical company continues to build out its early-stage oncology pipeline. The specific breakdown of the upfront payment alongside development and regulatory milestones was not disclosed in the press release.
Roche has signed a definitive merger agreement to acquire 89bio and its Phase III candidate pegozafermin, an FGF21 analogue for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH). The deal is expected to close in Q4 2025.
From Brisbane to London to Paris: Australian vaccine innovation sparks US$1.15 billion deal with french Sanofi with an additional US$450 million tied to clinical milestones and underscoring a major commitment to next-generation respiratory vaccines.
The planned US$10 billion acquisition of UK-based Verona Pharma by US pharmaceutical giant Merck & Co. underscores several key dynamics reshaping the global biotech industry. Not only does the deal reflect Merck’s strategic push to diversify in anticipation of the looming patent expiry of its blockbuster cancer drug Keytruda, but it also highlights the growing appeal of European biotech for US investors.
Austrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m.
Merger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services.
GSK takes over Elsie Biotechnologies in US$50m deal to boost its oligonucleotide-based drug platform and pipeline.
US pharma giant Merck Sharp & Dohme (MSD) is decided to acquire London-based ophtalmology expert Eyebiotech Ltd for upt to US$3bn., US$1.7bn in future milestones.
Essential Pharma has acquired Renaissance Pharma Ltd to commercialise the company’s Phase II program Hu14.18K322A in pedriatric high-risk neuroblastoma.
Novo Nordisk is set to acquire German miRNA blocker specialist Cardior Pharmaceuticals GmbH for up to €1.025bn including milestone payments.
Henk Vrieselaar - stock.adobe.com 
Gerd Altmann/pixabay.com
David_SMC from Pixabay